Noboru Numao
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Noboru Numao has a total of 81 co-authors. Here are the top co-authors by number of shared publications:
- Junichiro Ishioka
Department of Urology, Tokyo Medical and Dental University Graduate School, Tokyo, Japan
5 shared publications - Misao Yokoyama
Kyoto University
5 shared publications - Yasuhisa Fujii
Department of Urology Institute of Science Tokyo Tokyo Japan
4 shared publications - Yoh Matsuoka
Department of Urology Saitama Cancer Center Saitama Japan
4 shared publications - Hajime Tanaka
Department of Urology, Institute of Science Tokyo, Tokyo, Japan
3 shared publications J. Yonese
3 shared publications
Latest Publications
- 6 August 2026
- Published by Wiley in International Journal of Urology
- Vol. 33 (8)
Real‐World Outcomes of Olaparib Treatment in Japanese Patients With Metastatic Castration‐Resistant Prostate Cancer Harboring BRCA Pathogenic or Likely Pathogenic Variants
Background: Olaparib has demonstrated clinical benefit in patients with metastatic castration‐resistant prostate cancer (mCRPC) harboring BRCA pathogenic or likely pathogenic variants (PVs) in randomized clinical trials; however, multicenter real‐world data in Japanese patients remain limited. Methods: This multicenter retrospective study included Japanese patients with mCRPC who received olaparib between 2021 and 2025 at four institutions. Eligible patients had pathogenic or likely pathogenic BRCA1/2 variants identified by comprehensive genomic profiling or BRCA ‐specific testing (BRACAnalysis). Disease progression was defined as prostate‐specific antigen (PSA) progression or radiographic progression. Overall survival (OS) and progression‐free survival (PFS) were estimated using the Kaplan–Meier method. Results: Among 128 patients undergoing comprehensive genomic profiling, 18 (14%) were identified as having BRCA PVs, of whom 13 received olaparib. Among 239 patients tested by BRACAnalysis, 14 (6%) harbored BRCA PVs and all received olaparib. Overall, 27 patients with mCRPC harboring BRCA PVs were analyzed. The median duration of olaparib treatment was 8 months, with three patients treated for more than 30 months. One‐year OS rate was 80.6%, with a median OS of 18.4 months, and 1‐year PFS rate was 27.2% with a median PFS of 7.6 months. Grade 3 anemia occurred in 33% of patients and was manageable, with no grade 4 or 5 events observed. Conclusions: This multicenter retrospective study provides real‐world data on olaparib treatment in Japanese patients with mCRPC harboring BRCA PVs. The observed outcomes and safety profile were generally consistent with previous reports, although interpretation is limited by the small sample size, retrospective design, and heterogeneity of prior treatments.
- 6 August 2026
- Published by Wiley in International Journal of Urology
- Vol. 33 (8)
Real‐World Outcomes of Olaparib Treatment in Japanese Patients With Metastatic Castration‐Resistant Prostate Cancer Harboring BRCA Pathogenic or Likely Pathogenic Variants
Background: Olaparib has demonstrated clinical benefit in patients with metastatic castration‐resistant prostate cancer (mCRPC) harboring BRCA pathogenic or likely pathogenic variants (PVs) in randomized clinical trials; however, multicenter real‐world data in Japanese patients remain limited. Methods: This multicenter retrospective study included Japanese patients with mCRPC who received olaparib between 2021 and 2025 at four institutions. Eligible patients had pathogenic or likely pathogenic BRCA1/2 variants identified by comprehensive genomic profiling or BRCA ‐specific testing (BRACAnalysis). Disease progression was defined as prostate‐specific antigen (PSA) progression or radiographic progression. Overall survival (OS) and progression‐free survival (PFS) were estimated using the Kaplan–Meier method. Results: Among 128 patients undergoing comprehensive genomic profiling, 18 (14%) were identified as having BRCA PVs, of whom 13 received olaparib. Among 239 patients tested by BRACAnalysis, 14 (6%) harbored BRCA PVs and all received olaparib. Overall, 27 patients with mCRPC harboring BRCA PVs were analyzed. The median duration of olaparib treatment was 8 months, with three patients treated for more than 30 months. One‐year OS rate was 80.6%, with a median OS of 18.4 months, and 1‐year PFS rate was 27.2% with a median PFS of 7.6 months. Grade 3 anemia occurred in 33% of patients and was manageable, with no grade 4 or 5 events observed. Conclusions: This multicenter retrospective study provides real‐world data on olaparib treatment in Japanese patients with mCRPC harboring BRCA PVs. The observed outcomes and safety profile were generally consistent with previous reports, although interpretation is limited by the small sample size, retrospective design, and heterogeneity of prior treatments.
- 6 February 2023
- Published by Wiley in International Journal of Urology
- Vol. 30 (5) , 492-494
Doppler ultrasonography as a screening test for the detection of asymptomatic renal artery pseudoaneurysms following partial nephrectomy: A 15‐year single‐institution experience
- 6 February 2023
- Published by Wiley in International Journal of Urology
- Vol. 30 (5) , 492-494
Doppler ultrasonography as a screening test for the detection of asymptomatic renal artery pseudoaneurysms following partial nephrectomy: A 15‐year single‐institution experience
- 1 June 2021
- Published by Elsevier in European Urology
- Vol. 79, S829-S830
The three-dimensional reconstructed virtual images improve the reliability, accuracy, and efficiency of the R.E.N.A.L. nephrometry score for preoperative assessment
- 1 June 2021
- Published by Elsevier in European Urology
- Vol. 79, S829-S830
The three-dimensional reconstructed virtual images improve the reliability, accuracy, and efficiency of the R.E.N.A.L. nephrometry score for preoperative assessment
- Open Access
- 28 May 2019
- Published by Wiley in International Journal of Urology
- Vol. 26 (8) , 820-826
Impact of fluorodeoxyglucose uptake on positron emission tomography/computed tomography on chemosensitivity and survival in patients with metastatic urothelial carcinoma
Objectives To evaluate the impact of fluorodeoxyglucose uptake on positron emission tomography/computed tomography on chemosensitivity and survival in patients with metastatic urothelial carcinoma. Methods The present study assessed 51 metastatic urothelial carcinoma patients undergoing fluorodeoxyglucose positron emission tomography/computed tomography before first‐line systemic chemotherapy. Fluorodeoxyglucose uptake in metastases was evaluated using the maximum standardized uptake value, which was measured for all eligible lesions, and the highest value among the maximum standardized uptake value measurements in each case was defined as the highest maximum standardized uptake value. The associations between the highest maximum standardized uptake value and objective response rate to chemotherapy, progression‐free survival or cancer‐specific survival were analyzed. For cancer‐specific survival, the C‐index was compared between multivariate models that incorporated predictors in the Bajorin model including the Karnofsky performance status and the presence of visceral metastasis, and the Apolo model additionally including hemoglobin and albumin levels, with/without the highest maximum standardized uptake value. Results The median age was 69 years. The Karnofsky performance status was ≥80% for all patients. Visceral metastasis was observed in 12 patients (24%). The objective response rate, median progression‐free survival and median cancer‐specific survival were 61%, 9 and 26 months in the entire cohort, respectively. The higher highest maximum standardized uptake value was significantly associated with a lower objective response rate, shorter progression‐free survival and shorter cancer‐specific survival (P = 0.01, <0.001 and 0.004, respectively). On multivariate analyses, the highest maximum standardized uptake value was an independent predictor for all end‐points. In the multivariate models for cancer‐specific survival, the C‐index improved from 0.559 to 0.601 and from 0.604 to 0.652 by adding the highest maximum standardized uptake value to the parameter set of the Bajorin model and Apolo model, respectively. Conclusions Higher fluorodeoxyglucose uptake in metastases was significantly and independently associated with poor chemosensitivity and worse survival outcomes. Fluorodeoxyglucose positron emission tomography/computed tomography might aid in patient counseling and treatment decisions for metastatic urothelial carcinoma patients.
- 28 May 2019
- Published by Wiley in International Journal of Urology
- Vol. 26 (8) , 820-826
Open AccessImpact of fluorodeoxyglucose uptake on positron emission tomography/computed tomography on chemosensitivity and survival in patients with metastatic urothelial carcinoma
Objectives To evaluate the impact of fluorodeoxyglucose uptake on positron emission tomography/computed tomography on chemosensitivity and survival in patients with metastatic urothelial carcinoma. Methods The present study assessed 51 metastatic urothelial carcinoma patients undergoing fluorodeoxyglucose positron emission tomography/computed tomography before first‐line systemic chemotherapy. Fluorodeoxyglucose uptake in metastases was evaluated using the maximum standardized uptake value, which was measured for all eligible lesions, and the highest value among the maximum standardized uptake value measurements in each case was defined as the highest maximum standardized uptake value. The associations between the highest maximum standardized uptake value and objective response rate to chemotherapy, progression‐free survival or cancer‐specific survival were analyzed. For cancer‐specific survival, the C‐index was compared between multivariate models that incorporated predictors in the Bajorin model including the Karnofsky performance status and the presence of visceral metastasis, and the Apolo model additionally including hemoglobin and albumin levels, with/without the highest maximum standardized uptake value. Results The median age was 69 years. The Karnofsky performance status was ≥80% for all patients. Visceral metastasis was observed in 12 patients (24%). The objective response rate, median progression‐free survival and median cancer‐specific survival were 61%, 9 and 26 months in the entire cohort, respectively. The higher highest maximum standardized uptake value was significantly associated with a lower objective response rate, shorter progression‐free survival and shorter cancer‐specific survival (P = 0.01, <0.001 and 0.004, respectively). On multivariate analyses, the highest maximum standardized uptake value was an independent predictor for all end‐points. In the multivariate models for cancer‐specific survival, the C‐index improved from 0.559 to 0.601 and from 0.604 to 0.652 by adding the highest maximum standardized uptake value to the parameter set of the Bajorin model and Apolo model, respectively. Conclusions Higher fluorodeoxyglucose uptake in metastases was significantly and independently associated with poor chemosensitivity and worse survival outcomes. Fluorodeoxyglucose positron emission tomography/computed tomography might aid in patient counseling and treatment decisions for metastatic urothelial carcinoma patients.
- 15 March 2019
- Published by Elsevier in European Urology Supplements
- Vol. 18 (1) , e785
Combination of prebiopsy magnetic resonance imaging and systematic biopsy can efficiently predict ipsilateral negative lymph-node metastasis in prostate cancer treated with radical prostatectomy and extended pelvic lymph node dissection
- 15 March 2019
- Published by Elsevier in European Urology Supplements
- Vol. 18 (1) , e785
Combination of prebiopsy magnetic resonance imaging and systematic biopsy can efficiently predict ipsilateral negative lymph-node metastasis in prostate cancer treated with radical prostatectomy and extended pelvic lymph node dissection
- 11 March 2016
- Published by Elsevier in European Urology Supplements
- Vol. 15 (3) , e784
784 Impact of PI-RADS version 2 on MRI diagnosis for extracapsular extension of prostate cancer: A multireader study
- 11 March 2016
- Published by Elsevier in European Urology Supplements
- Vol. 15 (3) , e784
784 Impact of PI-RADS version 2 on MRI diagnosis for extracapsular extension of prostate cancer: A multireader study
- 11 March 2016
- Published by Elsevier in European Urology Supplements
- Vol. 15 (3) , e761
761 Prognostic significance of early CRP response for metastatic renal cell carcinoma treated with tyrosine kinase inhibitor
- 11 March 2016
- Published by Elsevier in European Urology Supplements
- Vol. 15 (3) , e761
761 Prognostic significance of early CRP response for metastatic renal cell carcinoma treated with tyrosine kinase inhibitor
- 11 March 2016
- Published by Elsevier in European Urology Supplements
- Vol. 15 (3) , e484
484 Renal dysfunction manifestation in patients with adrenal Cushing's syndrome after adrenalectomy
- 11 March 2016
- Published by Elsevier in European Urology Supplements
- Vol. 15 (3) , e484
484 Renal dysfunction manifestation in patients with adrenal Cushing's syndrome after adrenalectomy
- Open Access
- 1 December 2014
- Published by FapUNIFESP (SciELO) in International braz j urol
- Vol. 40 (6) , 842-845
New head-mounted display system applied to endoscopic management of upper urinary tract carcinomas
Key words: Urinary Tract; Ureteroscopy; Natural Orifice Endoscopic Surgery; Video-Assisted Surgery
- 1 December 2014
- Published by FapUNIFESP (SciELO) in International braz j urol
- Vol. 40 (6) , 842-845
Open AccessNew head-mounted display system applied to endoscopic management of upper urinary tract carcinomas
Key words: Urinary Tract; Ureteroscopy; Natural Orifice Endoscopic Surgery; Video-Assisted Surgery